(CercleFinance.com) – Merck KGaA announced on Monday the conclusion of a strategic collaboration agreement with the Chinese company Hengrui, with which it intends to develop a PARP inhibitor and an antibody-drug conjugate in the field of oncology.
Under the terms of the partnership, the German pharmaceutical group will have the rights to market the powerful new generation PARP-1 inhibitor developed by Hengrui outside of China.
The agreement also provides for the granting of an exclusive license, outside China, for the rights to an antibody-drug conjugate, with the possibility of co-promoting the two assets on the Chinese market.
In a press release, Merck says it is banking heavily on technologies such as ATR inhibitors, ATM gene mutation, DNA-PK activation or PARP inhibitors in the treatment of cancer.
Merck specifies that it plans to pay Hengrui a first initial payment of 160 million euros, which could be followed by a total of 1.4 billion euros, notably in the form of royalties, depending on progress. projects.
Listed on the Frankfurt Stock Exchange, Merck shares fell by more than 5% on Monday morning after these announcements.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
